Treatment of inflammation before stem cell transplant for immune disorders

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effectiveness of emapalumab and a combination of fludarabine and dexamethasone in reducing inflammation in patients with primary immune regulatory disorders and autoinflammatory conditions prior to receiving a stem cell transplant. The goal is to enhance the engraftment process, which is crucial for the success of the transplant. Participants will be monitored for their response to these treatments and how well they prepare for the transplant procedure.

Why it matters

Who can join: the full rules

Inclusion criteria:

1. Patients receiving first allo-HCT for the following immunologic conditions:

   * Primary Immune Regulatory Disorder with or without a genetic lesion as defined by the Primary Immune Deficiency Treatment Consortium (PIDTC)12 - Patients with autoinflammatory disorders evidenced by cytokine or inflammation assays with at least 1.5x ULN of measured cytokines (defined in section 4) and/or an elevated ferritin or ESR \> 2 ULN
   * For inclusion on the emapalumab group, the lesion must be related to the IFNγ pathway (or mediators thereof) with an elevated CXCL9 \>1.5 ULN OR sIL2R \>1.5 ULN (or already controlled on immune modulation, provided that CXCL9 or sIL2R levels were elevated prior to initiation of immune modulation).
   * Inclusion on the Fludarabine/dexamethasone group requires inflammation (as defined above) other than an IFNy pathway defect
2. Able to tolerate cytoreduction (based on adequate organ function as described below)
3. Patients of any age can enroll so long as they meet all other eligibility criteria
4. Adequate organ function is required, defined as follows:

   * Hepatic: Serum bilirubin ≤ 2 mg/dL, unless benign congenital hyperbilirubinemia. Patients with hyperbilirubinemia related to paroxysmal nocturnal hemoglobinuria or other hemolytic disorders related to their PIRD diagnosis are eligible.
   * Hepatic: AST, ALT, and alkaline phosphatase \< 2.5 times the upper limit of normal unless thought to be disease-related. Investigator will need to perform clinically indicated evaluations to assess if disease related or intrinsic liver disease. Additional testing may be done if clinically indicated, after the pre-transplant immune prophase and prior to start of conditioning as this will provide additional data to confirm disease related versus intrinsic liver dysfunction.
   * Renal: serum creatinine \<1.5x normal for age. If serum creatinine is outside the normal range, then CrCl \> 50 mL/min/1.73m\^2 (calculated or estimated) or GFR (mL/min/1.72m\^2) \>30% of predicted normal for age.
   * Cardiac: LVEF ≥ 50% by MUGA or resting echocardiogram.
   * Pulmonary: Pulmonary function testing (FEV1 and corrected DLCO) ≥ 50% predicted (pediatric patients unable to complete PFTs will need oxygen saturation as recorded by pulse oximetry of ≥92% on room air).
5. Adequate performance status:

   * Age ≥ 16 years: ECOG ≤ 1 or Karnofsky ≥ 70%
   * Age \< 16 years: Lansky 70%
6. Each patient must be willing to participate as a research subject and must sign an informed consent form or legal guardian with assent as appropriate.

Donor Inclusion Criteria:

1. Related Donors:

   * 8/8 or 7/8 HLA matched at A, B, C, and DRB1 loci, as tested by DNA analysis.
   * Haploidentical donors at A, B, C and DRB1 loci, as tested by DNA analysis
2. Unrelated Donors:

   * 8/8 or 7/8 matched at A, B, C, and DRB1 loci, as tested by DNA analysis.
3. Able to provide informed consent for the donation process per institutional standards.
4. Meet standard criteria for donor collection (e.g. National Marrow Donor Program Guidelines or collecting center guidelines as approved by treating physician).

Exclusion Criteria:

1. Uncontrolled infection at the time of enrollment.
2. Patients who have undergone previous allo-HCT.
3. Patient seropositivity for HIV I/II and/or HTLV I/II.
4. Females who are pregnant or breastfeeding.
5. Patients unwilling to use contraception during the study period.
6. Patient or parent or guardian unable to give informed consent or unable to comply with the treatment protocol including research tests.

Where it's running

• University of California, San Francisco
  San Francisco, California, United States Recruiting
• Children's Healthcare of Atlanta
  Atlanta, Georgia, United States Recruiting
• Columbia University Irving Medical Center
  New York, New York, United States Recruiting
• Children's Hospital of Philadelphia
  Philadelphia, Pennsylvania, United States Recruiting
• Texas Children's Hospital
  Houston, Texas, United States Recruiting
• Children's Hospital of Wisconsin
  Milwaukee, Wisconsin, United States Recruiting

Study contacts

• Principal investigator: Joseph Oved, MD — Columbia University
• Study coordinator: Joseph Oved, MD
• Email: jho2001@cumc.columbia.edu
• Phone: 212 305 9770

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Stem cell transplant for patients with immune system disorders

  This study is testing if a stem cell transplant from a matched donor can help people aged 4 to 69 with immune system disorders feel better and improve their health.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT04339777

• Transplantation of blood or marrow for treating immune system disorders

  This study is testing if getting blood or marrow transplants from healthy donors can help people aged 4 to 75 with serious immune system disorders feel better and stay healthy.

  Recruiting at 2 sites Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland and 1 other locations · NCT02579967

• ETHY-001 safety and activity in Thyroid Eye Disease (TED)

  This study tests ETHY-001 versus placebo to see if it is safe, tolerable, and shows activity in people with thyroid eye disease.

  Recruiting at 2 sites Phase 1 Ethyreal Bio, Inc. · Orland Park, Illinois and 2 other locations · NCT07885605

• Understanding congenital bone marrow failure and related disorders through a national network

  This project tests whether people with rare inherited bone marrow failure syndromes or related conditions really have the underlying genetic causes, by collecting data and samples across multiple centers.

  Recruiting at 4 sites Istituto Giannina Gaslini · Avellino and 3 other locations · NCT07877727

• Music-4-MS: A 12-week music-based program to support thinking skills in people with MS

  A 12-week music-based program is tested to see if it helps cognitive function and mood in people living with multiple sclerosis.

  Recruiting University of Texas at Austin · Austin, Texas · NCT07759115

• AMX0035 in adults with Type 1 Diabetes

  This study tests whether 24 weeks of the oral medication AMX0035 help improves metabolic health in adults with Type 1 Diabetes compared with a placebo.

  Recruiting Phase 2 University of Washington · Seattle, Washington and 1 other locations · NCT07699380

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.